izreloaded
2020-12-30

$Arcturus Therapeutics Ltd.(ARCT)$Arcturus believes cellular responses induced by its ** vaccine candidate will compensate for the underwhelming neutralizing antibody levels in its interim Phase I/II data.

Eng Eong Ooi, a member of Arcturus’ vaccine platform SAB, hypothesized the robust T cell responses were behind the low antibody production following the second 5 µg ARCT-021 administration.

Ooi said their data showed that antibodies were not necessary for protection against SARS-CoV-2. 

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • 哈V
    2020-12-31
    哈V
    but when its trial possibly comes to Phase 3 the covid crisis might be over already
    • 哈VReplyizreloaded: 
      why this vaccine is possibly cheaper? the current RNA vaccine can be as cheap as a few dollars per jab
    • 哈VReplyizreloaded: 

      do you have a position in this stock?

    • izreloadedReplyizreloaded: 
      Therefore there is a huge market and opportunIty for vAccines like arcturus which are single dose, cheaper and HaVe rhe abiltTy to prodUce mOre T Cells.
    • 哈VReplyizreloaded: 

      well I used to have positions in biotech and moderna but now hold none of their shares. indeed I shorted mrna the day its vaccine was declared. I've no position in this one. Good luck anyway.

    • izreloadedReply哈V: 
      I hAve positions in biontec, moderna and arcturus.
  • izreloaded
    2020-12-31
    izreloaded
    I have positions in biontec, moDerna and arcturus.
Leave a comment
8